Skip to content

Alt stock news

HomeTemblador54859Alt stock news
04.01.2021

ALT - Altimmune Inc. • BioPharmCatalyst NewsSee all news. 30 March 2020 Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine. GAITHERSBURG, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it is launching a collaboration with the University of Alabama at Home | Altimmune Our diverse pipeline includes treatments for NASH (ALT-801), chronic Hepatitis B (HepTcell TM), and conjugated immunostimulants for the treatment of cancer (ALT-702).In addition, we are developing intranasal vaccine programs for anthrax and influenza. OTC Markets | ALT

ALT Altimmune, Inc. Stock Quote - FINVIZ.com

Home - Alt News Subscribe to Alt News via Email. Enter your email address to subscribe to Alt News and receive notifications of new posts by email. Email Address . Subscribe . Except where otherwise noted, this website is licensed under a Creative Commons Attribution 3.0 Unported License. Content from Facebook is governed by Facebook License for posts that are ALT - Altimmune News - Barchart.com Find recent news headlines for a specific symbol on this page. Van Meerten Stock Picks. Jim Van Meerten's Daily Stock Picks highlights stocks you might want to consider for your portfolio, with Jim's editorials about current events and stock market commentary. Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations.

Find the latest news headlines from Altimmune, Inc. Common Stock (ALT) at Nasdaq.com.

See Altimmune price target based on 1 analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is $13.00 with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 348.28% increase from the last price of $2.90. All News for ALT : PharmAthene, Inc - Zacks.com Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results. All News for ALT : PharmAthene, Inc - Zacks.com

Why Altimmune Stock Is Skyrocketing Today - InvestorPlace

Real-time trade and investing ideas on Altimmune, Inc. ALT from the largest community of traders and investors. ALT | Complete Altimmune Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Get breaking news and analysis on Altimmune, Inc. (ALT) stock, price quote and chart, trading and investing tools. Prev Close 3.35, 52 Wk Low 1.51. Open 2.94, 52 Wk High 4.45. Day Low 2.90, Volume 3.1M. Day High 3.43, Avg 10D Vol 1.5M  Find the latest news headlines from Altimmune, Inc. Common Stock (ALT) at Nasdaq.com.

See Altimmune price target based on 1 analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is $13.00 with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 348.28% increase from the last price of $2.90.

Altimmune, Inc. (ALT) News – Find the latest company news headlines for Altimmune, Inc. and all the companies you research at NASDAQ.com Altimmune Inc. Stock Price (ALT) | Barron's View today's stock price, news and analysis for Altimmune Inc. (ALT). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and more. Is Altimmune Inc (ALT) Stock a Good Buy? - InvestorsObserver Mar 12, 2020 · Altimmune Inc stock is up 8.07% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.InvestorsObserver’s proprietary ranking system, gives ALT stock a score of 80 out of a possible 100.. That rank is primarily influenced by a long-term technical score of 99. ALT's rank also includes a short-term technical score of 72. ALT Stock Quote - Philab Holdings Corp - Bloomberg Markets Stock analysis for Philab Holdings Corp (ALT) including stock price, stock chart, company news, key statistics, fundamentals and company profile.